Wegovy 1mg FlexTouch

About

Wegovy 1mg FlexTouch contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, indicated for chronic weight management. It is prescribed for adults with obesity (Body Mass Index [BMI] of 30 kg/m² or greater) or those who are overweight (BMI of 27 kg/m² or greater) and have at least one weight-related comorbidity, such as hypertension, type 2 diabetes, or dyslipidemia. Semaglutide works by mimicking the natural GLP-1 hormone, which helps regulate appetite and food intake. It increases insulin secretion in a glucose-dependent manner, decreases glucagon secretion, and slows gastric emptying, leading to a feeling of fullness and reduced calorie intake.

This medication is intended to be used as an adjunct to a reduced-calorie diet and increased physical activity. The 1mg dose is part of a titration schedule, typically increasing gradually over several weeks to minimize gastrointestinal side effects, eventually reaching a maintenance dose. Regular medical supervision is essential to monitor progress and manage any potential adverse reactions, ensuring the safe and effective use of Wegovy in a comprehensive weight management program.

Uses

• Chronic weight management in adults.
• Treatment of obesity (BMI ≥30 kg/m²).
• Management of overweight (BMI ≥27 kg/m²) with weight-related comorbidities.
• Adjunct to a reduced-calorie diet and increased physical activity.

Directions For Use

Administer Wegovy 1mg FlexTouch once weekly via subcutaneous injection as directed by your healthcare provider. Rotate injection sites with each dose.

Benefits

• Promotes significant and sustained weight loss.
• Helps reduce appetite and increase satiety.
• May improve weight-related health conditions.
• Convenient once-weekly dosing schedule.
• Supports long-term weight management goals.
• Can lead to improvements in metabolic parameters.

Side Effects

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Abdominal pain
• Headache
• Fatigue
• Dizziness
• Dyspepsia
• Injection site reactions
• Hypoglycemia (especially with concomitant antidiabetic agents)
• Cholelithiasis (gallstones)

Safety Measures

• Alcohol - Use alcohol in moderation. Excessive alcohol intake may exacerbate gastrointestinal side effects or affect blood sugar levels, especially if you have diabetes.
• Pregnancy - Wegovy is not recommended during pregnancy. Animal studies have shown reproductive harm. Discontinue use at least 2 months before a planned pregnancy.
• Breastfeeding - It is unknown if semaglutide is excreted in human milk. The decision to breastfeed should consider the potential risks to the infant and the benefits of treatment to the mother. Consult your doctor.
• Liver - Generally safe for use in patients with mild to moderate hepatic impairment. Use with caution in severe liver impairment due to limited clinical experience; monitor for adverse effects.
• Kidney - Use with caution in patients with severe renal impairment or end-stage renal disease, as clinical experience is limited. No dose adjustment is typically needed for mild to moderate renal impairment.
• Lung - No specific contraindications or dose adjustments are required for patients with lung conditions. Wegovy is generally considered safe for use in individuals with respiratory issues.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.